Back to top

Analyst Blog

Valeant Pharmaceuticals International, Inc. (VRX - Snapshot Report) received positive news when the U.S. Food and Drug Administration (FDA) issued marketing clearance for Bausch + Lomb's newest frequent replacement silicone hydrogel contact lenses.

The lenses are made using the MoistureSeal Technology. The results from a multi-site study of Bausch + Lomb contact lenses with MoistureSeal technology showed that it offers superior comfort and vision as compared to other lenses. 

We note that Valeant acquired Bausch + Lomb in Aug 2013. 

With a history of 160 years, Bausch + Lomb currently has recognized prescription and over the counter (OTC) brands such as Besivance, Lotemax, Ocuvite and PreserVision and vision care brands such as Biotrue ONEday, PureVision, renu and Boston under its portfolio. 

The company also has surgical brands such as enVista, Storz, Stellaris and VICTUS under its extensive portfolio.

The new silicone hydrogel lenses will further strengthen its ophthalmology portfolio. 

We remind investors that Valeant acquired Bausch+Lomb to strengthen its ophthalmology portfolio, which was a miniscule portion of Valeant’s overall portfolio. 

We believe the acquisition will help Valeant to penetrate into the growing eye health market fueled by an aging patient population, an increased rate of diabetes, and increasing demand from the emerging markets. 

Concurrent with second-quarter results, Valeant upped its guidance for 2013 to include the Bausch+Lomb acquisition. Valeant now expects revenues between $5.8 billion and $6.2 billion, up from the previous projection of $4.4 billion – $4.8 billion. 

Earnings per share on a cash basis are now projected around $6.00 – $6.20, up from the earlier projection of $5.55 –$5.85. 

Valeant now expects synergies more than the earlier estimate of $800 million from this acquisition. Of the total projected synergies, $500 million is expected in 2013. 

We are impressed by the company’s integration efforts and increase in expected synergies.

Valeant currently carries a Zacks Rank #3 (Hold). Right now, Actelion Ltd. (ALIOF), Jazz Pharmaceuticals (JAZZ - Analyst Report), and Cempra, Inc. (CEMP - Snapshot Report) look attractive. While Actelion and Jazz Pharma carry a Zacks Rank #1(Strong Buy), Cempra carries a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
FELCOR LODG… FCH 10.47 +3.46%
COVENANT TR… CVTI 12.50 +3.22%
OLD DOMINIO… ODFL 63.50 +1.21%
FIRSTSERVIC… FSRV 56.19 +0.83%
CITI TRENDS… CTRN 20.26 +0.40%